- Research article
- Open Access
- Open Peer Review
Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway
- Yu-Shih Lin†1, 8,
- Yin-Yin Lin†2,
- Yao-Hsu Yang2, 3, 11,
- Chun-Liang Lin4, 5,
- Feng-Che Kuan6,
- Cheng-Nan Lu9,
- Geng-He Chang10, 11,
- Ming-Shao Tsai10,
- Cheng-Ming Hsu10,
- Reming-Albert Yeh10,
- Pei-Rung Yang2,
- I-Yun Lee2,
- Li-Hsin Shu2,
- Yu-Ching Cheng2,
- Hung-Te Liu2,
- Kuan-Der Lee7,
- De-Ching Chang8Email author and
- Ching-Yuan Wu2, 3Email author
© The Author(s). 2018
- Received: 8 November 2017
- Accepted: 16 April 2018
- Published: 9 May 2018
Breast cancer is the most common cancer in women and affects 1.38 million women worldwide per year. Antiestrogens such as tamoxifen, a selective estrogen receptor (ER) modulator, are widely used in clinics to treat ER-positive breast tumors. However, remissions of breast cancer are often followed by resistance to tamoxifen and disease relapse. Despite the increasing understanding of the resistance mechanisms, effective regimens for treating tamoxifen-resistant breast cancer are limited. Antrodia cinnamomea is a traditional medicinal mushroom native only to Taiwan. In this study, we aimed to examine in vitro effect of antrodia cinnamomea in the tamoxifen-resistant cancer.
Antrodia cinnamomea was studied for its biological activity against proliferation of tamoxifen-resistant breast cancer by XTT assay. Next, the underlying mechanism was studied by flow cytometry, qPCR and Western’s blotting assay.
Our results revealed that the ethanol extract of antrodia cinnamomea (AC) can inhibit the growth of breast cancer cells, including MCF-7 cell and tamoxifen-resistant MCF-7 cell lines. Combination treatment with AC and 10− 6 M tamoxifen have the better inhibitory effect on the proliferation of tamoxifen-resistant MCF-7 cells than only AC did. AC can induce apoptosis in these breast cancer cells. Moreover, it can suppress the mRNA expression of skp2 (S-phase kinase-associated protein 2) by increasing the expressions of miR-21-5p, miR-26-5p, and miR-30-5p in MCF-7 and tamoxifen-resistant MCF-7 cells.
These results suggest that the ethanol extract of antrodia cinnamomea could be a novel anticancer agent in the armamentarium of tamoxifen-resistant breast cancer management. Moreover, we hope to identify additional pure compounds that could serve as promising anti-breast cancer candidates for further clinical trials.
- Breast cancer
- Antrodia cinnamomea
Breast cancer is the most common cancer in women and affects 1.38 million women worldwide per year . In the past 20 years, the development of new therapeutics has significantly reduced mortality rates. Antiestrogens such as tamoxifen, a selective estrogen receptor modulator, are widely used in clinics to treat estrogen receptor (ER)-positive breast tumors. An adjuvant therapy study of tamoxifen demonstrated a 40 to 50% reduction in the odds of recurrence and reduced mortality and temporary remissions in 30 to 50% of patients with metastatic disease . However, remissions of breast cancer are often followed by resistance and disease relapse . Previous studies have reported several mechanisms associated with resistance to tamoxifen, including altered expression of microRNA [3, 4]. Despite the increasing understanding of the resistance mechanisms, effective regimens for treating tamoxifen-resistant breast cancer are limited. Therefore, developing treatment regimens for tamoxifen-resistant breast cancer that are more effective and accompanied by minimal adverse effects remains a priority in breast cancer research.
Antrodia cinnamomea (AC) is a medical mushroom native only to Taiwan and is originally found growing in the empty rotting trunk of Cinnamomum kanehirai Hay. AC has been reported to have anti-inflammatory, hepatoprotective, antitumor, antioxidant, and immunomodulatory properties [5–11]. In the past years, several compounds, including steroid acids, triterpenoids, and polysaccharides, have been isolated from AC [10, 12–18]. Some studies have reported that the extract of AC can inhibit the growth of breast cancer cell lines [19, 20]. Moreover, antrodin C, extracted from AC can inhibit epithelial-to-mesenchymal transition and the metastasis of breast cancer cells . However, the effects of AC on acquired tamoxifen-resistant breast cancer and the underlying mechanism remain unclear. In this study, we investigated the effects of the fruiting body extract of AC on tamoxifen-resistant breast cancer and identified the underlying mechanism.
Cell culture and treatment
MCF-7 cells (human breast cancer cell line) were obtained from the American Type Culture Collection. The MCF-7 cells were cultured in Eagle’s Minimum Essential Medium (EMEM) (Invitrogen Corp., Carlsbad, CA), supplemented with 10% FBS at 37 °C and 5% CO2. For the acquired tamoxifen resistant breast cancer cells, MCF-7 cells were cultured in Eagle’s Minimum Essential Medium containing 10% charcoal-stripped fetal bovine serum with 1 μM tamoxifen over a period of 3 months and then maintaining them in 10− 7 M tamoxifen for more than 9 months. Powdered fruiting bodies of 10 months cultivated dried Antrodia cinnamomea (250 g, brought form Fong Chun biotecology Co., Taiwan) were soaked in 500 ml ethanol for three days. The sample was filtered with filter paper while the residue was further extracted twice more under the same conditions. The filtrates collected from three separate extractions were combined and evaporated to dryness under vacuum (27 g). The extract was dissolved in ethanol and stored at − 20 °C. For all experiments, final concentrations of the tested compound were prepared by diluting the stock with ethanol. Antcin K, antcin C, antcin B, methyl antcinate B, eburicoic acid and dehydroeburicoic acid were kindly gifts from Dr. Lih-Geeng Chen. Human breast cancer cells were cultured to 60–70% confluence prior to treatment. Medium was then replaced with fresh medium containing AC in DMSO (dimethyl sulfoxide) at the indicated concentrations. Cells treated with DMSO alone were used as untreated controls. The parental cells without treatment were used as blank control.
The indicated breast cancer cell lines were plated at a density of 103 per well, in 96-well plates, in EMEM containing 10% FBS and 1% penicillin/streptomycin. Once attached, the medium was replaced with EMEM containing 10% FBS and 1% penicillin/streptomycin. The cells were then treated with indicated drugs for 24 or 48 h; and absorbance were measured using the XTT assay kit (Roche, Cat. No. 11465015001) according to the manufacturer’s instructions as described previously . The XTT formazan complex was quantitatively measured at 492 nm using an ELISA reader (Bio-Rad Laboratories, Inc.).
Human breast cancer cells (1 × 106 cells) were seeded in a 100-mm plate and cultured overnight before treatment. Then, the cells were treated with control or 10 μM of indicated drugs for 48 h. Then treated cells were detected by Annexin V-FITC Apoptosis Detection Kit (Strong Biotech Corporation, Cat No.: AVK250) and Mitoscreen JC-1 kit (Mitochondrial Membrane Potential Assay, BD Biosciences: 551302) according to the manufacturer’s instructions. In brief, at the end of the incubation period, the medium was removed. The treated cells were collected after washing by cold PBS. The supernatant was removed by centrifugation and then resuspended in indicated buffer by staining at room temperature in the dark for 15 min. The stained cells were analyzed by the flow cytometer BD FACSCanto (Becton Dickinson). Apoptosis of different developmental stages were studied by gating the respective population in the Dot Plots.
Quantitative real time PCR
Quantitative Real time PCR were performed as described previously [23, 24]. Total RNA was extracted from the breast cancer cells using the illustra™ RNAspin Mini RNA Isolation Kit (GE Healthcare, Cat. No. 25–0500) and according to the manufacturer’s instructions. Reverse transcription was performed using the Superscript first strand synthesis kit (Invitrogen, Number: 11904018). Quantitative real-time PCR analyses using the comparative CT method were performed on an ABI PRISM 7700 Sequence Detector System using the SYBR Green PCR Master Mix kit (Perkin Elmer, Applied Biosystems, Wellesley, MA, USA) according to the manufacturer’s instructions. Following initial incubation at 50 °C for 2 min and 10 min at 95 °C, amplification was performed for 40 cycles at 95 °C for 20 s, 65 °C for 20 s and 72 °C for 30 s. Primers used were: Skp2 forward, 5′-TTA GTC GGG AGA ACT TTC CAG GTG-3′ and Skp2 reverse, 5′-AGT CAC GTC TGG GTG CAG ATTT-3′. RhoA forward, 5′-GAG CAC ACA AGG CGG GAG-3′ and RhoA reverse, 5’-CTT GCA GAG CAG CTC TCG TAG-3′. GAPDH forward, 5’-TGC ACC ACC AAC TGC TTAGC-3′ and GAPDH reverse, 5’-GGC ATG GAC TGT GGT CATGA-3′. GAPDH was used as the housekeeping gene for data normalization. For microRNA, qPCR assay was performed in accordance with the previous study .
Total miRNA was extracted from breast cancer cells using the mirVana™ miRNA Isolation Kit (Life Technologies Corporation, Cat. No. AM1560) according to the manufacturer’s instructions. Reverse transcription was performed using TaqMan microRNA Reverse transcription kit (Life Technologies Corporation, Number: 4366596). Quantitative real-time PCR analyses using the comparative CT method were performed on an ABI PRISM 7700 Sequence Detector System using the SYBR Green PCR Master Mix kit (Perkin Elmer, Applied Biosystems, Wellesley, MA, USA) according to the manufacturer’s instructions. Following initial incubation at 50 °C for 2 min and 10 min at 95 °C, amplification was performed for 40 cycles at 95 °C for 20 s, 65 °C for 20 s and 72 °C for 30 s. Primers used were: miR-16 forward, 5′- CGC GCT AGC AGC ACG TAA AT-3′ and miR-16 reverse, 5′- GTG CAG GGT CCG AGG T-3′. miR-21-5p forward, 5′- GCC CGC TAG CTT ATC AGA CTG ATG-3′ and miR-21-5p reverse, 5′- GTG CAG GGT CCG AGG T-3′. miR-26-5p forward, 5′- CGC CGC TTC AAG TAA TTC AGG AT-3′ and miR-26-5p reverse, 5′- GTG CAG GGT CCG AGG T-3′. miR-30-5p forward, 5′- GCG TGT AAA CAT CCT CGA CTG G-3′ and miR-30-5p reverse, 5′- GCA GGG ACC GTG GT-3′. miR-16 was used as the housekeeping gene for data normalization.
Western blot analysis
Western blot analyses were performed as described previously [26, 27]. Cellular extracts of the human breast cancer cell line treated with DMSO or indicated compounds for 24 h were prepared according to the manufacturer’s instructions. The equal amounts of protein were fractionated on a 6 or 12% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were then blocked with 5% nonfat dried milk for 30 min and incubated in primary antibody for 3 h in room temperature. The primary antibodies used were: anti-PARP antibody (Cell Signaling, ratio: 1:1000), anti-Skp2 antibody (Cell Signaling, ratio: 1:1000), anti-β-actin antibody (Santa Cruz, IB: 1:10000). The primary antibody and secondary antibody were diluted with 1% nonfat dried milk in 1X TBST (Tris-Buffered Saline Tween-20). Blots were washed by 1X TBST and incubated in horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies (Santa Cruz, ratio: 1:5000) for one hour in room temperature. After washing by 1X TBST again, protein signal was detected by chemiluminescence, using the Super Signal substrate (Pierce, Number: 34087).
High-performance liquid chromatography (HPLC) conditions
HPLC analysis was performed in an Agilent 1100 HPLC system using a column (Nova-Pak® C18, 4 μm, 3.9 × 150 mm). The two solvents, trifluoroacetic acid (0.05%) and CH3CN were the A and B solvents, respectively, for the mobile phase. Gradient elution was programmed as follows: (A)/(B) = 95/5 (0 min) → (A)/(B) = 0/100 (40 min). Chromatograms were recorded at a flow of 0.6 ml/min and at a wavelength of 254 nm with the column maintained at 25 °C.
miRNA target prediction
Statistical analyses for cell line studies
All values were the means ± standard error of mean (SEM) of the replicate samples (n = 3 to 6, depending on the experiment) and experiments were repeated a minimum of three times. Differences between two groups were assessed using the unpaired two-tailed Student’s t-test or by ANOVA if more than two groups were analyzed. The Tukey test was used as a post-hoc test in ANOVA for testing the significance of pairwise group comparisons. P-values < 0.05 were considered statistically significant in all comparisons. SAS9.4 was used for all calculations.
The composition of AC
Effect of AC on the proliferation of different breast cancer cell lines
These data suggested that AC exhibits a potent growth inhibitory activity in human ER-positive breast cancer cells, including those resistant to tamoxifen. Combine therapy with tamoxifen have the better inhibitory effect on the proliferation of tamoxifen-resistant MCF-7 cells than only AC did.
Effects of AC on the apoptosis of breast cancer cells in vitro
AC reduces the protein expression and mRNA level of skp2
Effect of AC on microRNAs for regulating skp2
In previous studies, microRNAs have been reported to inhibit cancer cell proliferation and induce apoptosis by targeting the skp2 pathway [37, 38]. In Fig. 4e and f, we found the protein expression of Skp2 decreased in both ER-positive and tamoxifen-resistant breast cancer cells under AC treatment. Furthermore, qPCR showed that the mRNA expression of Skp2 and downstream genes, RhoA, was inhibited by treatment of both ER-positive and tamoxifen-resistant breast cancer cells with AC (Fig. 4a-d). MicroRNA may be involved in the mechanism of AC involving the skp2 signaling pathway.
MCF-7 is a stable tumor cell line derived from a patient with metastatic breast cancer; it contains ERs and is estrogen responsive. Moreover, it is the most widely used and best characterized cell line for investigating acquired tamoxifen resistance [39–43]. For tamoxifen-resistant MCF-7 cells, one proteome report demonstrated that tamoxifen-resistant breast cancer cells are characterized by downregulated ER signaling, the activation of alternative survival pathways, and enhanced cell motility, including RhoA protein . Our result revealed that AC exhibited a higher IC50 for tamoxifen-resistant MCF-7 cells (195.97 μg/mL) than that for MCF-7 cells (185.043 μg/mL). Thus, tamoxifen-resistant MCF-7 cells may activate some alternative survival pathways against these compounds. Moreover, AC can inhibit the mRNA expression of RhoA, the upregulated protein in tamoxifen-resistant breast cancer cells, in both the ER-positive and tamoxifen-resistant breast cancer cells (Fig. 4c and d). These results suggest that RhoA signaling may be an important pathway through which AC can inhibit the growth of both the ER-positive breast cancer cells and breast cancer cells with acquired tamoxifen resistance.
Some previous studies have demonstrated that AC extract can inhibit the growth of breast cancer cell lines [20, 21]. Shang et al. demonstrated that AC fruiting body extracts can deregulate the PI3K/Akt/mTOR signaling pathway and induce apoptosis in T47D breast cancer cells . Kumar et al. demonstrated that antrodin C attenuates the TGF-β1-induced epithelial mesenchymal transition, migration, and invasion of MCF-7 cells through the suppression of Smad2/3 and β-catenin signaling pathways . Su reported that ethyl acetate extracts of AC exhibited antiproliferation effects against MDA-MB-231 cells, a triple-negative breast cancer cell line . However, the effect of AC on the acquired tamoxifen-resistant breast cancer remains unclear. Our results revealed that AC could inhibit both the ER-positive and acquired tamoxifen-resistant MCF-7 cells. Our data also suggested that AC could be developed as a potential candidate against acquired tamoxifen-resistant breast cancer.
Shang et al. used tree different fruiting bodies of AC harvested at 3, 6, and 9 months to investigate their cytotoxicity against T47D cells, a human mammary ductal carcinoma cell line (ER-positive). After 48 h of treatment, the IC50 of T47D cells was 52.7 μg/mL (3-mo fruiting body), 122.6 μg/mL (6-mo fruiting body), and 141.9 μg/mL (9-mo fruiting body) . In our study, we used the 10-month fruiting body of AC; the IC50 values of tamoxifen-resistant MCF-7 and MCF-7 cells were 195.97 and 185.043 μg/mL, respectively. The difference between these results may be attributed to the different culture duration and different breast cancer cell lines. Our HPLC result revealed that the composites of AC included antcin K, antcin C, antcin B, methyl antcinate B, eburicoic acid, and dehydroeburicoic acid. In previous studies, antcin K has been shown to exhibit antitumor effects against hepatoma and leukemia [12, 29, 44]. Antcin C, antcin B, and eburicoic acid also exhibit antitumor effects against hepatoma [31, 45, 46]. Dehydroeburicoic acid exhibits antitumor effects against the breast cancer T47D cell line . Thus, dehydroeburicoic acid in AC may play an important role against breast cancer. However, numerous composites in AC remain unidentified. These composites also play an important role in the antitumor activity against breast cancer, including ER-positive and acquired tamoxifen-resistant breast cancer.
Bhatt et al. demonstrated tamoxifen can stimulate p38MAPK (p38 mitogen-activated protein kinases) to catalyze phosphorylation of Skp2 at serine-64 that drives ubiquitin-dependent proteasomal degradation of NKX3–1 to induce Oct-4 (octamer-binding transcription factor 4) gene expression in the presence of tamoxifen. These results suggested the crucial role of Skp2/p38MAPK/NKX3–1 mediated Oct-4 expression in driving tamoxifen resistance in MCF-7 cells . Previous studies have demonstrated that microRNAs such as miR-186 and miR-340 can inhibit cancer cell proliferation and induce apoptosis by targeting the Skp2 pathway [37, 38]. Another previous study demonstrated that AC exerts an inhibitory effect on breast cancer stem cells from the MDA-MB231 cell line. AC also downregulated several microRNAs, including miR-381 and miR-711, in MDA-MB231 cells, a triple-negative breast cancer cell line . However, the effect of AC on the expression of microRNA and Skp2 in ER-positive breast cancer and acquired tamoxifen-resistant breast cancer remain unclear. We first demonstrated that AC suppresses the mRNA expression of skp2 by increasing the expression of miR-21-5p, miR-26-5p, and miR-30-5p in MCF-7 and tamoxifen-resistant MCF-7 cells. In previous study, higher levels of miR-26a were significantly associated with clinical benefit and prolong time to progression on tamoxifen therapy of breast cancer . Higher expression levels of miR-30 family (miR-30a and miR-30c) were significantly associated with benefit of tamoxifen treatment and with longer progression free survival of breast cancer patients . Our data suggested AC inhibited different breast cancer cell lines through different microRNA signaling pathways. It is possible that AC may have clinical benefit of tamoxifen treatment in breast cancer patients. However, AC is the crude extract and contain a lot of pure compounds, many different mechanisms are involved through these different pure compounds [10, 12–18]. It is possible that Skp2 signaling pathway is not the only major pathway under the treatment of AC. In the further, we will investigate the in vivo and in vitro effect of these pure compounds on the breast cancer to clarify the clear mechanism of pure compounds with respect to tamoxifen resistance.
In summary, this is a novel study that demonstrated the mechanism by which AC can inhibit the proliferation of ER-positive and acquired tamoxifen-resistant breast cancer cells. The study results suggest that AC could be a novel anticancer agent in the armamentarium of breast cancer management. Furthermore, additional pure compounds from AC that might serve as promising anti-breast cancer candidates should be identified for further clinical trials.
This work was supported by grant CMRPG6C0262, CMRPG6D0343, CMRPG6F0011, CMRPG6F0661, CMRPG6F0551 and CMRPG6E0091 from Chang Gung Memorial Hospital, and MOST105–2320-B-182-006-MY3, NSC101–2320-B-182A-005 and NSC102–2320-B-182A-007 from Ministry of Science and Technology to Dr. Ching Yuan Wu.
Availability of data and materials
The datasets used and analyzed during the current study available from Ching-Yuan Wu, M.D., Ph. D. on reasonable request (firstname.lastname@example.org).
CYW conceived the idea and designed experiments and wrote manuscript. JYC, YHY, LHS, YSL, JL, HTL and YCC performed the experiments; CLL, CNL, YYL, FCK and PCC analyzed the data; HKL, KDL, YHT revised the manuscript. All authors reviewed and approved the final version.
Ethics approval and consent to participate
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.View ArticlePubMedGoogle Scholar
- Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005;23(11):2469–76.View ArticlePubMedGoogle Scholar
- Viedma-Rodriguez R, Baiza-Gutman L, Salamanca-Gomez F, Diaz-Zaragoza M, Martinez-Hernandez G, Ruiz Esparza-Garrido R, Velazquez-Flores MA, Arenas-Aranda D. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep. 2014;32(1):3–15.View ArticlePubMedGoogle Scholar
- Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer. 2014;6:1–13.PubMedPubMed CentralGoogle Scholar
- Chen JJ, Lin WJ, Liao CH, Shieh PC. Anti-inflammatory benzenoids from Antrodia camphorata. J Nat Prod. 2007;70(6):989–92.View ArticlePubMedGoogle Scholar
- Huang CC, Hsu MC, Huang WC, Yang HR, Hou CC. Triterpenoid-rich extract from Antrodia camphorata improves physical fatigue and exercise performance in mice. Evid Based Complement Alternat Med. 2012;2012:364741.PubMedPubMed CentralGoogle Scholar
- Hsu YL, Kuo PL, Cho CY, Ni WC, Tzeng TF, Ng LT, Kuo YH, Lin CC. Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kappaB pathway. Food Chem Toxicol. 2007;45(7):1249–57.View ArticlePubMedGoogle Scholar
- Ker YB, Peng CC, Chang WL, Chyau CC, Peng RY. Hepatoprotective bioactivity of the glycoprotein, antrodan, isolated from Antrodia cinnamomea mycelia. PLoS One. 2014;9(4):e93191.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu MD, Cheng MJ, Wang WY, Huang HC, Yuan GF, Chen JJ, Chen IS, Wang BC. Antioxidant activities of extracts and metabolites isolated from the fungus Antrodia cinnamomea. Nat Prod Res. 2011;25(16):1488–96.View ArticlePubMedGoogle Scholar
- Liu JJ, Huang TS, Hsu ML, Chen CC, Lin WS, Lu FJ, Chang WH. Antitumor effects of the partially purified polysaccharides from Antrodia camphorata and the mechanism of its action. Toxicol Appl Pharmacol. 2004;201(2):186–93.View ArticlePubMedGoogle Scholar
- Tsai MY, Hung YC, Chen YH, Chen YH, Huang YC, Kao CW, Su YL, Chiu HH, Rau KM. A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer. BMC Complement Altern Med. 2016;16(1):322.View ArticlePubMedPubMed CentralGoogle Scholar
- Du YC, Wu TY, Chang FR, Lin WY, Hsu YM, Cheng FT, Lu CY, Yen MH, Tsui YT, Chen HL, et al. Chemical profiling of the cytotoxic triterpenoid-concentrating fraction and characterization of ergostane stereo-isomer ingredients from Antrodia camphorata. J Pharm Biomed Anal. 2012;58:182–92.View ArticlePubMedGoogle Scholar
- Yeh CT, Rao YK, Yao CJ, Yeh CF, Li CH, Chuang SE, Luong JH, Lai GM, Tzeng YM. Cytotoxic triterpenes from Antrodia camphorata and their mode of action in HT-29 human colon cancer cells. Cancer Lett. 2009;285(1):73–9.View ArticlePubMedGoogle Scholar
- Cheng JJ, Yang CJ, Cheng CH, Wang YT, Huang NK, Lu MK. Characterization and functional study of Antrodia camphorata lipopolysaccharide. J Agric Food Chem. 2005;53(2):469–74.View ArticlePubMedGoogle Scholar
- Lee IH, Huang RL, Chen CT, Chen HC, Hsu WC, Lu MK. Antrodia camphorata polysaccharides exhibit anti-hepatitis B virus effects. FEMS Microbiol Lett. 2002;209(1):63–7.View ArticlePubMedGoogle Scholar
- Peng CC, Chen KC, Peng RY, Chyau CC, Su CH, Hsieh-Li HM. Antrodia camphorata extract induces replicative senescence in superficial TCC, and inhibits the absolute migration capability in invasive bladder carcinoma cells. J Ethnopharmacol. 2007;109(1):93–103.View ArticlePubMedGoogle Scholar
- Shen YC, Wang YH, Chou YC, Chen CF, Lin LC, Chang TT, Tien JH, Chou CJ. Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Planta Med. 2004;70(4):310–4.View ArticlePubMedGoogle Scholar
- Huang HC, Liaw CC, Yang HL, Hseu YC, Kuo HT, Tsai YC, Chien SC, Amagaya S, Chen YC, Kuo YH. Lanostane triterpenoids and sterols from Antrodia camphorata. Phytochemistry. 2012;84:177–83.View ArticlePubMedGoogle Scholar
- Su YK, Shih PH, Lee WH, Bamodu OA, Wu ATH, Huang CC, Tzeng YM, Hsiao M, Yeh CT, Lin CM. Antrodia cinnamomea sensitizes radio−/chemo-therapy of cancer stem-like cells by modulating microRNA expression. J Ethnopharmacol. 2017;207:47–56.View ArticlePubMedGoogle Scholar
- Shang KM, Su TH, Lee WL, Hsiao WW, Chiou CY, Ho BY, Wang SY, Shyur LF. Novel effect and the mechanistic insights of fruiting body extract of medicinal fungus Antrodia cinnamomea against T47D breast cancer. Phytomedicine. 2017;24:39–48.View ArticlePubMedGoogle Scholar
- Kumar KJ, Vani MG, Chueh PJ, Mau JL, Wang SY. Antrodin C inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via suppression of Smad2/3 and beta-catenin signaling pathways. PLoS One. 2015;10(2):e0117111.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu CY, Hsieh CY, Huang KE, Chang C, Kang HY. Cryptotanshinone down-regulates androgen receptor signaling by modulating lysine-specific demethylase 1 function. Int J Cancer. 2012;131(6):1423–34.View ArticlePubMedGoogle Scholar
- Lin YY, Lee IY, Huang WS, Lin YS, Kuan FC, Shu LH, Cheng YC, Yang YH, Wu CY. Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibit the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway. J Ethnopharmacol. 2017;209:305–16.View ArticlePubMedGoogle Scholar
- Lee IY, Lin YY, Yang YH, Lin YS, Lin CL, Lin WY, Cheng YC, Shu LH, Wu CY. Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway. BMC Pharmacol Toxicol. 2018;19(1):5.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.View ArticlePubMedPubMed CentralGoogle Scholar
- Wu CY, Cherng JY, Yang YH, Lin CL, Kuan FC, Lin YY, Lin YS, Shu LH, Cheng YC, Liu HT, et al. Danshen improves survival of patients with advanced lung cancer and targeting the relationship between macrophages and lung cancer cells. Oncotarget. 2017;8(53):90925–47.PubMedPubMed CentralGoogle Scholar
- Wu CY, Yang YH, Lin YY, Kuan FC, Lin YS, Lin WY, Tsai MY, Yang JJ, Cheng YC, Shu LH, et al. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway. Oncotarget. 2017;8(25):40246–63.PubMedPubMed CentralGoogle Scholar
- Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. elife. 2015;4Google Scholar
- Huang YL, Chu YL, Ho CT, Chung JG, Lai CI, Su YC, Kuo YH, Sheen LY. Antcin K, an active triterpenoid from the fruiting bodies of basswood-cultivated Antrodia cinnamomea, inhibits metastasis via suppression of integrin-mediated adhesion, migration, and invasion in human hepatoma cells. J Agric Food Chem. 2015;63(18):4561–9.View ArticlePubMedGoogle Scholar
- Du YC, Chang FR, Wu TY, Hsu YM, El-Shazly M, Chen CF, Sung PJ, Lin YY, Lin YH, Wu YC, et al. Antileukemia component, dehydroeburicoic acid from Antrodia camphorata induces DNA damage and apoptosis in vitro and in vivo models. Phytomedicine. 2012;19(8–9):788–96.View ArticlePubMedGoogle Scholar
- Hsieh YC, Rao YK, Whang-Peng J, Huang CY, Shyue SK, Hsu SL, Tzeng YM. Antcin B and its ester derivative from Antrodia camphorata induce apoptosis in hepatocellular carcinoma cells involves enhancing oxidative stress coincident with activation of intrinsic and extrinsic apoptotic pathway. J Agric Food Chem. 2011;59(20):10943–54.View ArticlePubMedGoogle Scholar
- Lee CI, Wu CC, Hsieh SL, Lee CL, Chang YP, Chang CC, Wang YZ, Wang JJ. Anticancer effects on human pancreatic cancer cells of triterpenoids, polysaccharides and 1,3-beta-d-glucan derived from the fruiting body of Antrodia camphorata. Food Funct. 2014;5(12):3224–32.View ArticlePubMedGoogle Scholar
- Lee YP, Tsai WC, Ko CJ, Rao YK, Yang CR, Chen DR, Yang MH, Yang CC, Tzeng YM. Anticancer effects of eleven triterpenoids derived from Antrodia camphorata. Anticancer Res. 2012;32(7):2727–34.PubMedGoogle Scholar
- Liu FS, Yang PY, Hu DN, Huang YW, Chen MJ. Antrodia camphorata induces apoptosis and enhances the cytotoxic effect of paclitaxel in human ovarian cancer cells. Int J Gynecol Cancer. 2011;21(7):1172–9.PubMedGoogle Scholar
- Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y, Guan X. Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 2016;15(10):1344–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY, Wu J, Nakayama KI, Kang HY, Huang HY, et al. Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol. 2010;12(5):457–67.View ArticlePubMedGoogle Scholar
- He W, Feng J, Zhang Y, Wang Y, Zang W, Zhao G. microRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2. Lab Investig. 2016;96(3):317–24.View ArticlePubMedGoogle Scholar
- Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incoronato M, Condorelli G, Banfi S, Verde P. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 2015;34(25):3240–50.View ArticlePubMedGoogle Scholar
- Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14(2):R45.View ArticlePubMedPubMed CentralGoogle Scholar
- Fan P, Yue W, Wang JP, Aiyar S, Li Y, Kim TH, Santen RJ. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology. 2009;150(5):2036–45.View ArticlePubMedPubMed CentralGoogle Scholar
- Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology. 2003;144(3):1032–44.View ArticlePubMedGoogle Scholar
- Leung EY, Kim JE, Askarian-Amiri M, Joseph WR, McKeage MJ, Baguley BC. Hormone resistance in two MCF-7 breast Cancer cell lines is associated with reduced mTOR signaling, decreased glycolysis, and increased sensitivity to cytotoxic drugs. Front Oncol. 2014;4:221.PubMedPubMed CentralGoogle Scholar
- Nawata H, Bronzert D, Lippman ME. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells. J Biol Chem. 1981;256(10):5016–21.PubMedGoogle Scholar
- Lai CI, Chu YL, Ho CT, Su YC, Kuo YH, Sheen LY. Antcin K, an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces mitochondria and endoplasmic reticulum stress-mediated apoptosis in human hepatoma cells. J Tradit Complement Med. 2016;6(1):48–56.View ArticlePubMedGoogle Scholar
- Gokila Vani M, Kumar KJ, Liao JW, Chien SC, Mau JL, Chiang SS, Lin CC, Kuo YH, Wang SY. Antcin C from Antrodia cinnamomea protects liver cells against free radical-induced oxidative stress and apoptosis in vitro and in vivo through Nrf2-dependent mechanism. Evid Based Complement Alternat Med. 2013;2013:296082.View ArticlePubMedPubMed CentralGoogle Scholar
- Su YC, Liu CT, Chu YL, Raghu R, Kuo YH, Sheen LY. Eburicoic acid, an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces ER stress-mediated autophagy in human hepatoma cells. J Tradit Complement Med. 2012;2(4):312–22.View ArticlePubMedPubMed CentralGoogle Scholar
- Bhatt S, Stender JD, Joshi S, Wu G, Katzenellenbogen BS. OCT-4: a novel estrogen receptor-alpha collaborator that promotes tamoxifen resistance in breast cancer cells. Oncogene. 2016;35(44):5722–34.View ArticlePubMedGoogle Scholar
- Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, Sleijfer S, Foekens JA, et al. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat. 2012;133(3):937–47.Google Scholar
- Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(1):43–51.View ArticlePubMedGoogle Scholar